The immunopathology of sepsis and potential therapeutic targets (original) (raw)

• Funk, D. J., Parrillo, J. E. & Kumar, A. Sepsis and septic shock: a history. Crit. Care Clin. 25, 83–101 (2009).
  Article PubMed Google Scholar
• Bone, R. C., Sibbald, W. J. & Sprung, C. L. The ACCP–SCCM Consensus Conference on sepsis and organ failure. Chest 101, 1481–1483 (1992).
  Article CAS PubMed Google Scholar
• Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801–810 (2016). This article describes the most recent consensus definition of sepsis.
  Article CAS PubMed PubMed Central Google Scholar
• Marshall, J. C. Why have clinical trials in sepsis failed? Trends Mol. Med. 20, 195–203 (2014).
  Article PubMed Google Scholar
• Cohen, J. et al. Sepsis: a roadmap for future research. Lancet Infect. Dis. 15, 581–614 (2015).
  Article PubMed Google Scholar
• Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
  Article CAS PubMed Google Scholar
• Chan, J. K. et al. Alarmins: awaiting a clinical response. J. Clin. Invest. 122, 2711–2719 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Deutschman, C. S. & Tracey, K. J. Sepsis: current dogma and new perspectives. Immunity 40, 463–475 (2014).
  Article CAS PubMed Google Scholar
• Gentile, L. F. et al. Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J. Trauma Acute Care Surg. 72, 1491–1501 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Wiersinga, W. J., Leopold, S. J., Cranendonk, D. R. & van der Poll, T. Host innate immune responses to sepsis. Virulence 5, 36–44 (2014).
  Article PubMed Google Scholar
• Merle, N. S., Noe, R., Halbwachs-Mecarelli, L., Fremeaux-Bacchi, V. & Roumenina, L. T. Complement system part II: role in immunity. Front. Immunol. 6, 257 (2015).
  PubMed PubMed Central Google Scholar
• Guo, R. F. & Ward, P. A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 23, 821–852 (2005).
  Article CAS PubMed Google Scholar
• Silasi-Mansat, R. et al. Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood 116, 1002–1010 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Shao, Z., Nishimura, T., Leung, L. L. & Morser, J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J. Thromb. Haemost. 13, 1090–1102 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34–45 (2013).
  Article CAS PubMed Google Scholar
• Levi, M. & van der Poll, T. Coagulation and sepsis. Thromb. Res. 149, 38–44 (2016).
  Article CAS PubMed Google Scholar
• Nieman, M. T. Protease-activated receptors in hemostasis. Blood 128, 169–177 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Danese, S., Vetrano, S., Zhang, L., Poplis, V. A. & Castellino, F. J. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 115, 1121–1130 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Kerschen, E. J. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J. Exp. Med. 204, 2439–2448 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Warren, B. L. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286, 1869–1878 (2001).
  Article CAS PubMed Google Scholar
• Abraham, E. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA 290, 238–247 (2003).
  Article CAS PubMed Google Scholar
• Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699–709 (2001).
  Article CAS PubMed Google Scholar
• Ranieri, V. M. et al. Drotrecogin alfa (activated) in adults with septic shock. N. Engl. J. Med. 366, 2055–2064 (2012).
  Article CAS PubMed Google Scholar
• Sorensen, O. E. & Borregaard, N. Neutrophil extracellular traps — the dark side of neutrophils. J. Clin. Invest. 126, 1612–1620 (2016).
  Article PubMed PubMed Central Google Scholar
• Yipp, B. G. & Kubes, P. NETosis: how vital is it? Blood 122, 2784–2794 (2013).
  Article CAS PubMed Google Scholar
• Czaikoski, P. G. et al. Neutrophil extracellular traps induce organ damage during experimental and clinical sepsis. PLoS ONE 11, e0148142 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• von Bruhl, M. L. et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 209, 819–835 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Opal, S. M. & van der Poll, T. Endothelial barrier dysfunction in septic shock. J. Intern. Med. 277, 277–293 (2015).
  Article CAS PubMed Google Scholar
• Darwish, I. & Liles, W. C. Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction. Virulence 4, 572–582 (2013).
  Article PubMed PubMed Central Google Scholar
• Tressel, S. L. et al. A matrix metalloprotease–PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. EMBO Mol. Med. 3, 370–384 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Sanchez, T. Sphingosine-1-phosphate signaling in endothelial disorders. Curr. Atheroscler. Rep. 18, 31 (2016).
  Article CAS PubMed Google Scholar
• Mikacenic, C. et al. Biomarkers of endothelial activation are associated with poor outcome in critical illness. PLoS ONE 10, e0141251 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Claushuis, T. A. et al. Thrombocytopenia is associated with a dysregulated host response in critically ill sepsis patients. Blood 127, 3062–3072 (2016).
  Article CAS PubMed Google Scholar
• Wong, C. H., Jenne, C. N., Petri, B., Chrobok, N. L. & Kubes, P. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat. Immunol. 14, 785–792 (2013). This paper demonstrates the tight interaction between haemostasis and innate immunity by showing that platelets and Kupffer cells act together in a mechanism that rapidly clears Gram-positive blood-borne bacteria.
  Article CAS PubMed PubMed Central Google Scholar
• de Stoppelaar, S. F. et al. Thrombocytopenia impairs host defense in gram-negative pneumonia-derived sepsis in mice. Blood 124, 3781–3790 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• de Stoppelaar, S. F., van 't Veer, C. & van der Poll, T. The role of platelets in sepsis. Thromb. Haemost. 112, 666–677 (2014).
  Article PubMed Google Scholar
• Kelly-Scumpia, K. M. et al. B cells enhance early innate immune responses during bacterial sepsis. J. Exp. Med. 208, 1673–1682 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Rauch, P. J. et al. Innate response activator B cells protect against microbial sepsis. Science 335, 597–601 (2012). This paper describes innate response activator B cells as key components of the innate immune response that facilitates bacterial clearance during sepsis.
  Article CAS PubMed PubMed Central Google Scholar
• Weber, G. F. et al. Interleukin-3 amplifies acute inflammation and is a potential therapeutic target in sepsis. Science 347, 1260–1265 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Hotchkiss, R. S., Monneret, G. & Payen, D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 13, 862–874 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Boomer, J. S. et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 306, 2594–2605 (2011). This article reports that patients who die in the ICU following sepsis, when compared with patients who die of non-sepsis aetiologies, have biochemical, flow cytometric and immunohistochemical findings that are consistent with immunosuppression.
  Article CAS PubMed PubMed Central Google Scholar
• Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc. Natl Acad. Sci. USA 106, 6303–6308 (2009).
  Article PubMed PubMed Central Google Scholar
• Shao, R. et al. Monocyte programmed death ligand-1 expression after 3–4 days of sepsis is associated with risk stratification and mortality in septic patients: a prospective cohort study. Crit. Care 20, 124 (2016).
  Article PubMed PubMed Central Google Scholar
• Venet, F. et al. Human CD4+CD25+ regulatory T lymphocytes inhibit lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-dependent mechanism. J. Immunol. 177, 6540–6547 (2006).
  Article CAS PubMed Google Scholar
• Scumpia, P. O. et al. Treatment with GITR agonistic antibody corrects adaptive immune dysfunction in sepsis. Blood 110, 3673–3681 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Pastille, E. et al. Modulation of dendritic cell differentiation in the bone marrow mediates sustained immunosuppression after polymicrobial sepsis. J. Immunol. 186, 977–986 (2011).
  Article CAS PubMed Google Scholar
• Hotchkiss, R. S. et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J. Immunol. 168, 2493–2500 (2002).
  Article CAS PubMed Google Scholar
• Scumpia, P. O. et al. CD11c+ dendritic cells are required for survival in murine polymicrobial sepsis. J. Immunol. 175, 3282–3286 (2005).
  Article CAS PubMed Google Scholar
• Carson, W. F., Cavassani, K. A., Dou, Y. & Kunkel, S. L. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 6, 273–283 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114 (2008).
  Article CAS PubMed Google Scholar
• Foster, S. L., Hargreaves, D. C. & Medzhitov, R. Gene-specific control of inflammation by TLR-induced chromatin modifications. Nature 447, 972–978 (2007).
  Article CAS PubMed Google Scholar
• Chan, C., Li, L., McCall, C. E. & Yoza, B. K. Endotoxin tolerance disrupts chromatin remodeling and NF-κB transactivation at the IL-1β promoter. J. Immunol. 175, 461–468 (2005).
  Article CAS PubMed Google Scholar
• El Gazzar, M. et al. Chromatin-specific remodeling by HMGB1 and linker histone H1 silences proinflammatory genes during endotoxin tolerance. Mol. Cell. Biol. 29, 1959–1971 (2009).
  Article CAS PubMed Google Scholar
• De Santa, F. et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 130, 1083–1094 (2007).
  Article CAS PubMed Google Scholar
• De Santa, F. et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J. 28, 3341–3352 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, T. F., Yoza, B. K., El Gazzar, M., Vachharajani, V. T. & McCall, C. E. NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance. J. Biol. Chem. 286, 9856–9864 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Netea, M. G., Quintin, J. & van der Meer, J. W. Trained immunity: a memory for innate host defense. Cell Host Microbe 9, 355–361 (2011). This paper introduces the term trained immunity to describe the phenomenon that mammalian innate immunity exhibits an immunological memory of past insults.
  Article CAS PubMed Google Scholar
• Blok, B. A., Arts, R. J., van Crevel, R., Benn, C. S. & Netea, M. G. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. J. Leukoc. Biol. 98, 347–356 (2015).
  Article CAS PubMed Google Scholar
• Quintin, J. et al. Candida albicans infection affords protection against reinfection via functional reprogramming of monocytes. Cell Host Microbe 12, 223–232 (2012).
  Article CAS PubMed Google Scholar
• Saeed, S. et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science 345, 1251086 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Cheng, S. C. et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science 345, 1250684 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Arts, R. J. et al. Glutaminolysis and fumarate accumulation integrate immunometabolic and epigenetic programs in trained immunity. Cell Metab. 24, 807–819 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Yoshida, K. et al. The transcription factor ATF7 mediates lipopolysaccharide-induced epigenetic changes in macrophages involved in innate immunological memory. Nat. Immunol. 16, 1034–1043 (2015).
  Article CAS PubMed Google Scholar
• Novakovic, B. et al. β-Glucan reverses the epigenetic state of LPS-induced immunological tolerance. Cell 167, 1354–1368 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Andersson, U. & Tracey, K. J. Reflex principles of immunological homeostasis. Annu. Rev. Immunol. 30, 313–335 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Koopman, F. A. et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 113, 8284–8289 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• O'Neill, L. A., Kishton, R. J. & Rathmell, J. A guide to immunometabolism for immunologists. Nat. Rev. Immunol. 16, 553–565 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1β through HIF-1α. Nature 496, 238–242 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Mills, E. L. et al. Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell 167, 457–470 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, T. F., Vachharajani, V. T., Yoza, B. K. & McCall, C. E. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 287, 25758–25769 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Lachmandas, E. et al. Microbial stimulation of different Toll-like receptor signalling pathways induces diverse metabolic programmes in human monocytes. Nat. Microbiol. 2, 16246 (2016).
  Article CAS PubMed Google Scholar
• Cheng, S. C. et al. Broad defects in the energy metabolism of leukocytes underlie immunoparalysis in sepsis. Nat. Immunol. 17, 406–413 (2016). This paper shows that leukocytes from patients with sepsis who have immunoparalysis demonstrate a generalized metabolic defect at the level of both glycolysis and oxidative metabolism.
  Article CAS PubMed Google Scholar
• Dickson, R. P. The microbiome and critical illness. Lancet Respir. Med. 4, 59–72 (2016).
  Article PubMed Google Scholar
• Prescott, H. C., Dickson, R. P., Rogers, M. A., Langa, K. M. & Iwashyna, T. J. Hospitalization type and subsequent severe sepsis. Am. J. Respir. Crit. Care Med. 192, 581–588 (2015).
  Article PubMed PubMed Central Google Scholar
• Schirmer, M. et al. Linking the human gut microbiome to inflammatory cytokine production capacity. Cell 167, 1125–1136 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Clarke, T. B. et al. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16, 228–231 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gauguet, S. et al. Intestinal microbiota of mice influences resistance to Staphylococcus aureus pneumonia. Infect. Immun. 83, 4003–4014 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Schuijt, T. J. et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. Gut 65, 575–583 (2016).
  Article CAS PubMed Google Scholar
• Karmarkar, D. & Rock, K. L. Microbiota signalling through MyD88 is necessary for a systemic neutrophilic inflammatory response. Immunology 140, 483–492 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Bo, L. et al. Probiotics for preventing ventilator-associated pneumonia. Cochrane Database Syst. Rev. 25, CD009066 (2014).
  Google Scholar
• Besselink, M. G. et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371, 651–659 (2008).
  Article PubMed Google Scholar
• Han, S., Shannahan, S. & Pellish, R. Fecal microbiota transplant: treatment options for Clostridium difficile infection in the intensive care unit. J. Intensive Care Med. 31, 577–586 (2016).
  Article PubMed Google Scholar
• Li, Q. et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. Crit. Care 19, 37 (2015).
  Article PubMed PubMed Central Google Scholar
• Sweeney, T. E. & Wong, H. R. Risk stratification and prognosis in sepsis: what have we learned from microarrays? Clin. Chest Med. 37, 209–218 (2016).
  Article PubMed PubMed Central Google Scholar
• Scicluna, B. P. et al. A molecular biomarker to diagnose community-acquired pneumonia on intensive care unit admission. Am. J. Respir. Crit. Care Med. 192, 826–835 (2015).
  Article CAS PubMed Google Scholar
• van Vught, L. A. et al. Incidence, risk factors, and attributable mortality of secondary infections in the intensive care unit after admission for sepsis. JAMA 315, 1469–1479 (2016). This is a large observational study showing that ICU-acquired infections only modestly contribute to mortality in patients admitted with sepsis.
  Article CAS PubMed Google Scholar
• van Vught, L. A. et al. Comparative analysis of the host response to community-acquired and hospital-acquired pneumonia in critically ill patients. Am. J. Respir. Crit. Care Med. 194, 1366–1374 (2016).
  Article CAS PubMed Google Scholar
• Burnham, K. L. et al. Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am. J. Respir. Crit. Care Med. http://dx.doi.org/10.1164/rccm.201608-1685OC (2016).
• Xiao, W. et al. A genomic storm in critically injured humans. J. Exp. Med. 208, 2581–2590 (2011). This study demonstrates that in patients with severe blunt trauma, the early leukocyte genomic response is characterized by an increase in the expression of genes involved in systemic inflammatory and innate immune responses, and concomitant suppression of genes involved in adaptive immunity.
  Article CAS PubMed PubMed Central Google Scholar
• Davenport, E. E. et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir. Med. 4, 259–271 (2016). This study carried out in patients with severe community-acquired pneumonia reveals two distinct sepsis response signatures that are based on analyses of the blood leukocyte transcriptome; one of the signatures identifies individuals with an immunosuppressed phenotype.
  Article PubMed PubMed Central Google Scholar
• Shalova, I. N. et al. Human monocytes undergo functional re-programming during sepsis mediated by hypoxia-inducible factor-1α. Immunity 42, 484–498 (2015).
  Article CAS PubMed Google Scholar
• Opal, S. M., Dellinger, R. P., Vincent, J. L., Masur, H. & Angus, D. C. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C? Crit. Care Med. 42, 1714–1721 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Leentjens, J., Kox, M., van der Hoeven, J. G., Netea, M. G. & Pickkers, P. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change? Am. J. Respir. Crit. Care Med. 187, 1287–1293 (2013).
  Article CAS PubMed Google Scholar
• Patil, N. K., Bohannon, J. K. & Sherwood, E. R. Immunotherapy: a promising approach to reverse sepsis-induced immunosuppression. Pharmacol. Res. 111, 688–702 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• van Vught, L. A. et al. The host response in sepsis patients developing intensive care unit-acquired secondary infections. Am. J. Respir. Crit. Care Med. http://dx.doi.org/10.1164/rccm.201606-1225OC (2017).
• Cruz, D. N. et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301, 2445–2452 (2009).
  Article CAS PubMed Google Scholar
• Payen, D. M. et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med. 41, 975–984 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01046669 (2016).
• Mass Device. Spectral Medical's Toraymyxin fails pivotal trial. MassDevice http://www.massdevice.com/spectral-medicals-toraymyxin-fails-pivotal-trial/ (2016).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02288975 (2017).
• Kang, J. H. et al. An extracorporeal blood-cleansing device for sepsis therapy. Nat. Med. 20, 1211–1216 (2014).
  Article CAS PubMed Google Scholar
• Arad, G. et al. Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock. PLoS Biol. 9, e1001149 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Ramachandran, G. et al. CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis. J. Infect. Dis. 211, 995–1003 (2015).
  Article CAS PubMed Google Scholar
• Bulger, E. M. et al. A novel drug for treatment of necrotizing soft-tissue infections: a randomized clinical trial. JAMA Surg. 149, 528–536 (2014).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02469857 (2017).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02246595 (2016).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01598831 (2017).
• Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am. J. Respir. Crit. Care Med. 186, 838–845 (2012).
  Article CAS PubMed Google Scholar
• Docke, W. D. et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat. Med. 3, 678–681 (1997).
  Article CAS PubMed Google Scholar
• Delsing, C. E. et al. Interferon-γ as adjunctive immunotherapy for invasive fungal infections: a case series. BMC Infect. Dis. 14, 166 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Nalos, M. et al. Immune effects of interferon γ in persistent staphylococcal sepsis. Am. J. Respir. Crit. Care Med. 185, 110–112 (2012).
  Article PubMed Google Scholar
• Rochman, Y., Spolski, R. & Leonard, W. J. New insights into the regulation of T cells by γc family cytokines. Nat. Rev. Immunol. 9, 480–490 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Unsinger, J. et al. IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. J. Immunol. 184, 3768–3779 (2010).
  Article CAS PubMed Google Scholar
• Kasten, K. R. et al. Interleukin-7 (IL-7) treatment accelerates neutrophil recruitment through γδ T-cell IL-17 production in a murine model of sepsis. Infect. Immun. 78, 4714–4722 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Venet, F. et al. IL-7 restores lymphocyte functions in septic patients. J. Immunol. 189, 5073–5081 (2012).
  Article CAS PubMed Google Scholar
• Mackall, C. L., Fry, T. J. & Gress, R. E. Harnessing the biology of IL-7 for therapeutic application. Nat. Rev. Immunol. 11, 330–342 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02640807 (2016).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02797431 (2017).
• Inoue, S. et al. IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. J. Immunol. 184, 1401–1409 (2010).
  Article CAS PubMed Google Scholar
• Conlon, K. C. et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33, 74–82 (2015).
  Article CAS PubMed Google Scholar
• Meisel, C. et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am. J. Respir. Crit. Care Med. 180, 640–648 (2009).
  Article CAS PubMed Google Scholar
• Hall, M. W. et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 37, 525–532 (2011).
  Article CAS PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02361528 (2016).
• Bo, L., Wang, F., Zhu, J., Li, J. & Deng, X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit. Care 15, R58 (2011).
  Article PubMed PubMed Central Google Scholar
• Pardoll, D. M. Immunology beats cancer: a blueprint for successful translation. Nat. Immunol. 13, 1129–1132 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02576457 (2017).
• Shubin, N. J. et al. BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction. J. Leukoc. Biol. 92, 593–603 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Inoue, S. et al. Dose-dependent effect of anti-CTLA-4 on survival in sepsis. Shock 36, 38–44 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tuthill, C., Rios, I. & McBeath, R. Thymosin α 1: past clinical experience and future promise. Ann. NY Acad. Sci. 1194, 130–135 (2010).
  Article CAS PubMed Google Scholar
• Wu, J. et al. The efficacy of thymosin α 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Crit. Care 17, R8 (2013).
  Article PubMed PubMed Central Google Scholar
• Feng, Z., Shi, Q., Fan, Y., Wang, Q. & Yin, W. Ulinastatin and/or thymosin α1 for severe sepsis: a systematic review and meta-analysis. J. Trauma Acute Care Surg. 80, 335–340 (2016).
  Article PubMed Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02867267 (2016).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02647554 (2016).
• Walter, J., Ware, L. B. & Matthay, M. A. Mesenchymal stem cells: mechanisms of potential therapeutic benefit in ARDS and sepsis. Lancet. Respir. Med. 2, 1016–1026 (2014).
  Article CAS PubMed Google Scholar
• Kingsley, S. M. & Bhat, B. V. Could stem cells be the future therapy for sepsis? Blood Rev. 30, 439–452 (2016).
  Article PubMed Google Scholar
• Nemeth, K. et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 15, 42–49 (2009).
  Article CAS PubMed Google Scholar
• Monsel, A. et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am. J. Respir. Crit. Care Med. 192, 324–336 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02883803 (2016).
• US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02421484 (2017).
• Larsen, R. et al. A central role for free heme in the pathogenesis of severe sepsis. Sci. Transl Med. 2, 51ra71 (2010).
  Article CAS PubMed Google Scholar
• Martins, R. et al. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Nat. Immunol. 17, 1361–1372 (2016).
  Article CAS PubMed Google Scholar
• Vachharajani, V. T. et al. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. J. Leukoc. Biol. 96, 785–796 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Wang, X. et al. Sirtuin-2 regulates sepsis inflammation in ob/ob mice. PLoS ONE 11, e0160431 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Pierrakos, C. & Vincent, J. L. Sepsis biomarkers: a review. Crit. Care 14, R15 (2010).
  Article PubMed PubMed Central Google Scholar
• Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250–1256 (2003).
  Article PubMed Google Scholar
• Vincent, J. L. et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 22, 707–710 (1996).
  Article CAS PubMed Google Scholar
• Gaieski, D. F., Edwards, J. M., Kallan, M. J. & Carr, B. G. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit. Care Med. 41, 1167–1174 (2013).
  Article PubMed Google Scholar
• Fleischmann, C. et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am. J. Respir. Crit. Care Med. 193, 259–272 (2016).
  Article CAS PubMed Google Scholar
• Kaukonen, K. M., Bailey, M., Suzuki, S., Pilcher, D. & Bellomo, R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311, 1308–1316 (2014). This large observational study in Australia and New Zealand finds that absolute mortality in severe sepsis decreased from 35.0% to 18.4% between 2000 and 2012, which represents an annual rate of absolute decrease of 1.3%.
  Article CAS PubMed Google Scholar
• Rhodes, A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2016. Crit. Care Med. 45, 486–552 (2017). This is the most recent version of the consensus guidelines for the management of sepsis and septic shock.
  Article PubMed Google Scholar
• Iwashyna, T. J., Ely, E. W., Smith, D. M. & Langa, K. M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304, 1787–1794 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Prescott, H. C., Osterholzer, J. J., Langa, K. M., Angus, D. C. & Iwashyna, T. J. Late mortality after sepsis: propensity matched cohort study. BMJ 353, i2375 (2016).
  Article PubMed PubMed Central Google Scholar
• Yende, S. et al. Long-term quality of life among survivors of severe sepsis: analyses of two international trials. Crit. Care Med. 44, 1461–1467 (2016).
  Article CAS PubMed PubMed Central Google Scholar